AstraZeneca ends R&D in India


Pharmaceutical firm AstraZeneca (AZ) is quitting its R&D site in Bangalore, India. The closure means 168 employees, researching neglected tropical diseases, tuberculosis (TB) and malaria, will lose their jobs as AZ drops its early-stage research into these areas.

The company will retain more advanced projects, such as AZD5847, which is in Phase II trials against TB. It will also outsource the site’s current product development functions, or transfer them to Macclesfield, UK. However, AZ confirmed it will maintain access to its compound library for open innovation projects in neglected diseases.

The closure is part of AZs ongoing restructuring programme, which began last year, will cost a total of 1600 jobs worldwide and see the company’s main UK R&D activities move from Alderley Park to Cambridge. After the closure, AZ will have just over 1000 staff in India, across manufacturing, sales and marketing roles.


Related Content

Succour for India's struggling scientists

21 January 2015 Managing Change

news image

The Right to Research foundation is helping Indian researchers to work their way into a job, as Rajesh Parishwad finds out

Global AstraZeneca restructuring will cost 1600 jobs

19 March 2013 Business

news image

Firm will focus drug development efforts in three strategic R&D centres in the UK, Sweden and the US

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent